European Journal of Clinical Pharmacology

, Volume 30, Issue 3, pp 331–334 | Cite as

Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing

  • S. W. Sanders
  • N. Haering
  • H. Mosberg
  • H. Jaeger
Originals

Summary

Twenty-four healthy volunteers participated in a study on the disposition of ergotamine following oral and rectal administration. Plasma samples were collected surrounding each dose of medication and a new mass spectrometry method was used for quantitation of the samples. A mean peak plasma concentration of 454 pg/ml was measured an average of 50 min following a 2 mg rectal dose. In contrast, the 2 mg oral dose produced a mean peak plasma concentration of 21 pg/ml an average of 69 min following the dose. Area under the concentration time curve indicated a relative bioavailability of 5% for the oral dosage form. Conflicting data on ergotamine disposition highlight the factors which may be responsible for determining bioavailability and pharmacologic activities of the compound.

Key words

ergotamine pharmacokinetics volunteers mass spectrometry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rall TW, Schleifer LS (1980) Oxytocin, prostaglandins, ergot alkaloids, and other agents. In: Gilman AG, Goodman LS, Gilman A (eds) The Pharmacologic basis of therapeutics, 6th edn. Macmillan, New York, pp 939–947Google Scholar
  2. 2.
    Robayo JR (1983) Vascular headache. In: Katcher BS, Young LY, Koda-Kimble MA (eds) Applied therapeutics. The clinical use of drugs, 3rd edn. Applied Therapeutics, San Francisco, pp 1105–7Google Scholar
  3. 3.
    Winholz M (ed, 1983) The Merck Index, 10th edn. Merck & Co., Inc., Rahway, p 3611Google Scholar
  4. 4.
    Kleimola TT (1978) Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay. Br J Clin Pharmacol 6: 255–260Google Scholar
  5. 5.
    Van Mansvelt FJW, Greving JE, De Zeelum RA (1978) Identification of ergot peptide alkaloids based on gas liquid chromatography of the peptide moiety. J Chromatogr 151: 113–120Google Scholar
  6. 6.
    Edlund PO (1981) Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr 226: 107–115Google Scholar
  7. 7.
    Schran HF, Schwarz HJ, Talbot KC, Loeffler LJ (1979) Specific radioimmunoassay of ergot peptide alkaloids in plasma. Clin Chem 25: 1928–1933Google Scholar
  8. 8.
    Ala-Hurula V, Myllylae VV, Arvela P, Kaerki NT, Hokkanen E (1979) Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 16: 355–60Google Scholar
  9. 9.
    Ibraheem JJ, Paalzow L, Tfelt-Hansen P (1983) Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 16: 695–699Google Scholar
  10. 10.
    Haering N, Schubert R, Settlage JA, Sanders SW (1985) The measurement of ergotamine in human plasma by triple sector quadrupole mass spectrometry with negative ion chemical ionization. Biom Mass Spectrom 12: 197–199Google Scholar
  11. 11.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
  12. 12.
    Aellig WH, Nuesch E (1977) Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15: 106–112Google Scholar
  13. 13.
    Aellig WH (1984) Investigation of the venoconstrictor effect of 8'hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol 26: 239–242Google Scholar
  14. 14.
    Mueller-Schweinitzer E (1984) What is known about the action of dihydroergotamine on the vasculature in man? Int J Clin Pharmacol Ther Toxicol 22: 677–682Google Scholar
  15. 15.
    Semenowicz-Siuda K, Markeiwicz A, Korczynska-Wardecka J (1984) Cirdadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 12: 653–658Google Scholar
  16. 16.
    Hurwitz GA, Webb JG, Walle T, Bai SA, Daniell HB, Gourley L, Loadholt CB, Gaffney TE (1983) Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol 16: 599–608Google Scholar
  17. 17.
    Melander A, McLean A (1983) Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet 8: 286–296Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • S. W. Sanders
    • 1
  • N. Haering
    • 1
  • H. Mosberg
    • 1
  • H. Jaeger
    • 1
  1. 1.L.A.B. GmbH & Co., Neu UlmFederal Republic of Germany
  2. 2.Drug Research Center, Ward 4EUniversity of Utah Medical CenterSalt Lake CityUSA

Personalised recommendations